BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33522429)

  • 1. Introduction of typhoid vaccine in the expanded immunization program of Pakistan.
    Aslam F; Yue Y; Aziz M
    Hum Vaccin Immunother; 2021 Jul; 17(7):2132. PubMed ID: 33522429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions.
    Mogasale V; Ramani E; Park IY; Lee JS
    Hum Vaccin Immunother; 2017 Sep; 13(9):2017-2024. PubMed ID: 28604164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.
    Yousafzai MT; Karim S; Qureshi S; Kazi M; Memon H; Junejo A; Khawaja Z; Ur Rehman N; Ansari MS; Ali R; Ujjan IU; Lohana HM; Memon NM; Hussain M; Nigar R; Bar-Zeev N; Qamar FN
    Lancet Glob Health; 2021 Aug; 9(8):e1154-e1162. PubMed ID: 34297962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.
    Shakya M; Neuzil KM; Pollard AJ
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S770-S774. PubMed ID: 34374785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gavi Support for Typhoid Conjugate Vaccines: Moving From Global Investments to Country Introduction.
    Soble A; Patel Z; Sosler S; Hampton L; Johnson H
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S160-S164. PubMed ID: 32725236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
    Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.
    Lo NC; Gupta R; Stanaway JD; Garrett DO; Bogoch II; Luby SP; Andrews JR
    J Infect Dis; 2018 Nov; 218(suppl_4):S232-S242. PubMed ID: 29444257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas.
    Birkhold M; Mwisongo A; Pollard AJ; Neuzil KM
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S781-S787. PubMed ID: 34528085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
    Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
    Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries.
    Debellut F; Hendrix N; Pitzer VE; Neuzil KM; Constenla D; Bar-Zeev N; Marfin A; Pecenka C
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S154-S160. PubMed ID: 30845321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revised Global Typhoid Vaccination Policy.
    Bentsi-Enchill AD; Hombach J
    Clin Infect Dis; 2019 Feb; 68(Suppl 1):S31-S33. PubMed ID: 30767001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018-2022.
    Hancuh M; Walldorf J; Minta AA; Tevi-Benissan C; Christian KA; Nedelec Y; Heitzinger K; Mikoleit M; Tiffany A; Bentsi-Enchill AD; Breakwell L
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(7):171-176. PubMed ID: 36795626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?
    Andrews JR; Qamar FN; Charles RC; Ryan ET
    N Engl J Med; 2018 Oct; 379(16):1493-1495. PubMed ID: 30332569
    [No Abstract]   [Full Text] [Related]  

  • 16. Projecting the cost of introducing typhoid conjugate vaccine (TCV) in the national immunization program in Malawi using a standardized costing framework.
    Debellut F; Mkisi R; Masoo V; Chisema M; Mwagomba D; Mtenje M; Limani F; Mategula D; Zimba B; Pecenka C
    Vaccine; 2022 Mar; 40(12):1741-1746. PubMed ID: 35153097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Typhoid Conjugate Vaccines and Enteric Fever Control: Where to Next?
    Steele AD; Carey ME; Kumar S; MacLennan CA; Ma LF; Diaz Z; Zaidi AKM
    Clin Infect Dis; 2020 Jul; 71(Suppl 2):S185-S190. PubMed ID: 32725223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?
    Jamka LP; Simiyu KW; Bentsi-Enchill AD; Mwisongo AJ; Matzger H; Marfin AA; Pollard AJ; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S171-S176. PubMed ID: 30845328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of typhoid conjugate vaccine against culture-confirmed typhoid in a peri-urban setting in Karachi: A case-control study.
    Batool R; Tahir Yousafzai M; Qureshi S; Ali M; Sadaf T; Mehmood J; Ashorn P; Naz Qamar F
    Vaccine; 2021 Sep; 39(40):5858-5865. PubMed ID: 34465474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities for Typhoid Vaccination in India.
    Srinivasan M; Sindhu KN; John J; Kang G
    Indian Pediatr; 2019 Jun; 56(6):453-458. PubMed ID: 31278221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.